Menopausal changes in the myometrium: an investigation using a GnRH agonist model.
Thirty-four premenopausal women were randomized to receive 3.75 mg of leuprorelin acetate depot or placebo for 8 weeks before hysterectomy. Postoperatively, the myometrium was examined by two independent pathologists and the pathologic features were graded. Computer analysis was used to assess myometrial cellularity and arterial wall structure (on hematoxylin and eosin-stained sections) and vascularity (on sections immunostained for Factor VIII-related antigen). The cellularity of the gonadotrophin-releasing hormone agonist-treated myometrium was higher than the controls with less stromal edema. Focal myometrial hyalinization was present in a minority of cases, all in the gonadotrophin-releasing hormone agonist-treated cases. The arteries in the gonadotrophin-releasing hormone agonist-treated uteri underwent atrophy of the tunica media and had significantly more perivascular fibrosis. The number of vessels per 100 myocytes also was decreased. Hypoestrinism secondary to leuprorelin treatment leads to myocyte atrophy, decreased stromal edema, atrophy of the arcuate arteries, and decreased myometrial vascularity.
Weeks
A D
AD
Department of Obstetrics and Gynecology, St James's University Hospital, Leeds, United Kingdom.
Wilkinson
N
N
Arora
D S
DS
Duffy
S R
SR
Wells
M
M
Walker
J J
JJ
D001158:Arteries / Q000473:pathology; D001284:Atrophy; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D004487:Edema / Q000473:pathology; D004958:Estradiol / Q000097:blood; D005260:Female; D005355:Fibrosis; D006801:Humans; D016729:Leuprolide / Q000008:administration & dosage*; D008593:Menopause; D008954:Models, Biological; D009215:Myometrium / Q000098:blood supply / Q000187:drug effects / Q000473:pathology*; D010919:Placebos; D017154:Stromal Cells / Q000473:pathology
D003692:Delayed-Action Preparations; D010919:Placebos; D004958:Estradiol; D016729:Leuprolide